Cardiovascular disease risk reduction with sleep apnea treatment

Girardin Jean-Louis, Clinton D. Brown, Ferdinand Zizi, Gbenga Ogedegbe, Carla Boutin-Foster, Joseph Gorga, Samy I. McFarlane

Research output: Contribution to journalArticle

Abstract

Cardiovascular diseases are the leading cause of death among adults in developed countries. An increase in prevalent cardiovascular risk factors (e.g., obesity, hypertension and diabetes) has led to a concerted effort to raise awareness of the need to use evidence-based strategies to help patients at risk of developing cardiovascular disease and to reduce their likelihood of suffering a stroke. Sleep apnea has emerged as an important risk factor for the development of cardiovascular disease. Epidemiologic and clinical evidence has prompted the American Heart Association to issue a scientific statement describing the need to recognize sleep apnea as an important target for therapy in reducing cardiovascular disease risks. This article examines evidence supporting associations of sleep apnea with cardiovascular disease and considers evidence suggesting cardiovascular risk reductions through sleep apnea treatment. Perspectives on emerging therapeutic approaches and promising areas of clinical and experimental research are also discussed.

Original languageEnglish (US)
Pages (from-to)995-1005
Number of pages11
JournalExpert Review of Cardiovascular Therapy
Volume8
Issue number7
DOIs
StatePublished - 2010

Fingerprint

Sleep Apnea Syndromes
Risk Reduction Behavior
Cardiovascular Diseases
Therapeutics
Developed Countries
Cause of Death
Obesity
Stroke
Hypertension
Research

Keywords

  • cardiovascular disease
  • diabetes
  • dyslipidemia
  • hypertension
  • obesity
  • sleep apnea

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Internal Medicine
  • Medicine(all)

Cite this

Jean-Louis, G., Brown, C. D., Zizi, F., Ogedegbe, G., Boutin-Foster, C., Gorga, J., & McFarlane, S. I. (2010). Cardiovascular disease risk reduction with sleep apnea treatment. Expert Review of Cardiovascular Therapy, 8(7), 995-1005. https://doi.org/10.1586/erc.10.55

Cardiovascular disease risk reduction with sleep apnea treatment. / Jean-Louis, Girardin; Brown, Clinton D.; Zizi, Ferdinand; Ogedegbe, Gbenga; Boutin-Foster, Carla; Gorga, Joseph; McFarlane, Samy I.

In: Expert Review of Cardiovascular Therapy, Vol. 8, No. 7, 2010, p. 995-1005.

Research output: Contribution to journalArticle

Jean-Louis, G, Brown, CD, Zizi, F, Ogedegbe, G, Boutin-Foster, C, Gorga, J & McFarlane, SI 2010, 'Cardiovascular disease risk reduction with sleep apnea treatment', Expert Review of Cardiovascular Therapy, vol. 8, no. 7, pp. 995-1005. https://doi.org/10.1586/erc.10.55
Jean-Louis, Girardin ; Brown, Clinton D. ; Zizi, Ferdinand ; Ogedegbe, Gbenga ; Boutin-Foster, Carla ; Gorga, Joseph ; McFarlane, Samy I. / Cardiovascular disease risk reduction with sleep apnea treatment. In: Expert Review of Cardiovascular Therapy. 2010 ; Vol. 8, No. 7. pp. 995-1005.
@article{9413a7471957400f8a512c0ef92cfec2,
title = "Cardiovascular disease risk reduction with sleep apnea treatment",
abstract = "Cardiovascular diseases are the leading cause of death among adults in developed countries. An increase in prevalent cardiovascular risk factors (e.g., obesity, hypertension and diabetes) has led to a concerted effort to raise awareness of the need to use evidence-based strategies to help patients at risk of developing cardiovascular disease and to reduce their likelihood of suffering a stroke. Sleep apnea has emerged as an important risk factor for the development of cardiovascular disease. Epidemiologic and clinical evidence has prompted the American Heart Association to issue a scientific statement describing the need to recognize sleep apnea as an important target for therapy in reducing cardiovascular disease risks. This article examines evidence supporting associations of sleep apnea with cardiovascular disease and considers evidence suggesting cardiovascular risk reductions through sleep apnea treatment. Perspectives on emerging therapeutic approaches and promising areas of clinical and experimental research are also discussed.",
keywords = "cardiovascular disease, diabetes, dyslipidemia, hypertension, obesity, sleep apnea",
author = "Girardin Jean-Louis and Brown, {Clinton D.} and Ferdinand Zizi and Gbenga Ogedegbe and Carla Boutin-Foster and Joseph Gorga and McFarlane, {Samy I.}",
year = "2010",
doi = "10.1586/erc.10.55",
language = "English (US)",
volume = "8",
pages = "995--1005",
journal = "Expert Review of Cardiovascular Therapy",
issn = "1477-9072",
publisher = "Expert Reviews Ltd.",
number = "7",

}

TY - JOUR

T1 - Cardiovascular disease risk reduction with sleep apnea treatment

AU - Jean-Louis, Girardin

AU - Brown, Clinton D.

AU - Zizi, Ferdinand

AU - Ogedegbe, Gbenga

AU - Boutin-Foster, Carla

AU - Gorga, Joseph

AU - McFarlane, Samy I.

PY - 2010

Y1 - 2010

N2 - Cardiovascular diseases are the leading cause of death among adults in developed countries. An increase in prevalent cardiovascular risk factors (e.g., obesity, hypertension and diabetes) has led to a concerted effort to raise awareness of the need to use evidence-based strategies to help patients at risk of developing cardiovascular disease and to reduce their likelihood of suffering a stroke. Sleep apnea has emerged as an important risk factor for the development of cardiovascular disease. Epidemiologic and clinical evidence has prompted the American Heart Association to issue a scientific statement describing the need to recognize sleep apnea as an important target for therapy in reducing cardiovascular disease risks. This article examines evidence supporting associations of sleep apnea with cardiovascular disease and considers evidence suggesting cardiovascular risk reductions through sleep apnea treatment. Perspectives on emerging therapeutic approaches and promising areas of clinical and experimental research are also discussed.

AB - Cardiovascular diseases are the leading cause of death among adults in developed countries. An increase in prevalent cardiovascular risk factors (e.g., obesity, hypertension and diabetes) has led to a concerted effort to raise awareness of the need to use evidence-based strategies to help patients at risk of developing cardiovascular disease and to reduce their likelihood of suffering a stroke. Sleep apnea has emerged as an important risk factor for the development of cardiovascular disease. Epidemiologic and clinical evidence has prompted the American Heart Association to issue a scientific statement describing the need to recognize sleep apnea as an important target for therapy in reducing cardiovascular disease risks. This article examines evidence supporting associations of sleep apnea with cardiovascular disease and considers evidence suggesting cardiovascular risk reductions through sleep apnea treatment. Perspectives on emerging therapeutic approaches and promising areas of clinical and experimental research are also discussed.

KW - cardiovascular disease

KW - diabetes

KW - dyslipidemia

KW - hypertension

KW - obesity

KW - sleep apnea

UR - http://www.scopus.com/inward/record.url?scp=77954481278&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77954481278&partnerID=8YFLogxK

U2 - 10.1586/erc.10.55

DO - 10.1586/erc.10.55

M3 - Article

C2 - 20602560

AN - SCOPUS:77954481278

VL - 8

SP - 995

EP - 1005

JO - Expert Review of Cardiovascular Therapy

JF - Expert Review of Cardiovascular Therapy

SN - 1477-9072

IS - 7

ER -